Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Hamilton Thorne Ltd T.HTL

Alternate Symbol(s):  HTLZF

Hamilton Thorne Ltd. is a provider of precision instruments, consumables, software and services to assisted reproductive technologies (ART), research, and cell biology markets. The Company markets its products and services under the Hamilton Thorne, Gynemed, Planer, Tek-Event, IVFtech, Microptic, and Embryotech Laboratories brands. It also provides an array of third-party equipment and... see more

TSX:HTL - Post Discussion

Hamilton Thorne Ltd > Market normally awards consistency
View:
Post by Possibleidiot01 on Aug 17, 2023 11:56am

Market normally awards consistency

Not so much in terms of HTL. Growth rate seems to be about 10% plus consistently. Maybe FX tailwinds and some M +A help.

Outlook

Mr. Wolf continued, “We continue to feel that our company is in a great position as demand for our products and services remains strong based on the positive trends in our field and we expect to continue to have organic sales growth in the 10% range in the second half of the year. Also, while we faced 4-5% currency headwinds in Q1, these impacts largely disappeared in Q2 and, if the current trends continue, we should see some tailwinds in the second half of the year.”

Commenting on the Company’s M&A activities, Francesco Fragasso, the Company’s CFO stated, “We have an extensive pipeline and are actively working on multiple acquisition opportunities. With liquidity of approximately $26.4 million from our significant cash on hand and unused lines of credit, along with further debt capacity, we are well positioned to continue to execute on our acquisition program.”



Comment by dogatcat on Aug 17, 2023 1:15pm
Hamliton-Thorne's time will come.  Nice to see the double-digit growth in both sales and EBITDA.  They also pushed some equipent sales which will add a nice boost.   This is a very low volume stock.  This morning, someone sold 400 shares at $1.29.  You can't buy a large quanitty of this stock under $1.50.    
Comment by dogatcat on Aug 17, 2023 1:17pm
Rememeber -  it is now coming common place for business and orgnizations to pay for nearly all costs related to IVF, just like they do in Europe.  That is going to increase this business 10 fold as it rolls out.  Japan is offering $$$$ subsidies for this therapy as well.   They need more children.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities